Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery process including hit confirmation, lead generation, lead optimization, and other studies. Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the Food & Drug Administration (FDA).
Since the last edition of Kalorama's Report on the outsourcing of discovery of novel compounds in the pharmaceutical industry, the industry has seen dramatic change. Pharmaceutical companies facing cutbacks in R&D budgets and new demands for novel products need to outsource aspects of their operations. Core functions once kept in-house such as the discovery of potential new drugs are now commonly outsourced. Kalorama Information's Outsourcing in Drug Discovery captures this trend, offering unparalleled coverage of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers in China, India, Russia and Eastern Europe is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market.
Segments covered in this report with market size estimates include:
- Chemistry Services
- Building Blocks
- Compound Synthesis
- Process Research
- Other Services
- Biology Services
- Protein Expression
- Structural Analysis
- Target Validation
- Pathways Analysis
- Other Services
- Screening Services
- Assay Development
- Primary Screening
- Secondary Screening
- Lead Optimization
- Early ADMET
- Analogues Creation
- Computational Support
- Other services
In addition to market data and forecasts, the report covers issues such as:
- Current outsourcing in drug discovery market size and future forecast
- R&D scale-backs at major companies
- The fastest-growing services for outsourcers
- Logistics, IP, regulatory and other issues in China, India and Eastern Europe
- Common discovery outsourcing pitfalls and how companies overcame them
- What factors should a client consider when deciding whether to do a project in-house or outsource it?
- The choice of a domestic outsourcing partner, or an overseas supplier?
- Best practices when working with a CRO
- Strategic vs. tactical outsourcing models
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, science, medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical, biotechnology and contract research organizations included marketing directors, division managers, and product representatives.